{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:54:17Z","timestamp":1770706457274,"version":"3.49.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["R24 AI118397"],"award-info":[{"award-number":["R24 AI118397"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>We examine the current understanding of the multidisciplinary aspects of hepatitis B cure research, such as socio-behavioral sciences, ethics, community engagement, and translational and implementation science.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>The peer-reviewed literature on the multi-disciplinary aspects of HBV cure research is gradually expanding, although several areas still require attention. These deficiencies include: the acceptability of HBV treatment discontinuations, HBV-related stigma, the impact of co-infections (e.g., HIV), and the translation of discoveries to resource-limited settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review highlights the importance of a multidisciplinary framework that bridges socio-behavioral sciences, ethics, community engagement, and translational and implementation science to help ensure the development of an effective, acceptable, scalable and equitable HBV cure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11904-025-00763-y","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T06:28:23Z","timestamp":1762583303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Envisioning a Multidisciplinary HBV Cure Research Agenda"],"prefix":"10.1007","volume":"22","author":[{"given":"Karine","family":"Dub\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chari","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Yendewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward R.","family":"Cachay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Sugarman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe L.","family":"Thio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debika","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"763_CR1","unstructured":"WHO. Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries [Internet]. 2024 [cited 2024 Jul 4]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240091672"},{"issue":"9","key":"763_CR2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"BS Sheena","year":"2022","unstructured":"Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796\u2013829.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"763_CR3","unstructured":"WHO. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021 [Internet]. 2021 [cited 2023 May 11]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240027077"},{"key":"763_CR4","doi-asserted-by":"crossref","unstructured":"Cheng Z, Lin P, Cheng N. HBV\/HIV coinfection: impact on the development and clinical treatment of liver diseases. Frontiers in Medicine. Volume 8. Frontiers Media S.A.; 2021. pp. 1\u201315.","DOI":"10.3389\/fmed.2021.713981"},{"issue":"1","key":"763_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jama.2019.19775","volume":"323","author":"A Lerner","year":"2020","unstructured":"Lerner A, Eisinger R, Fauci A. Comorbidities in persons with HIV: the lingering challenge. JAMA. 2020;323(1):19\u201320.","journal-title":"JAMA"},{"issue":"3","key":"763_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/gutjnl-2016-313009","volume":"66","author":"J Sugarman","year":"2017","unstructured":"Sugarman J, Revill P, Zoulim F, Yazdanpanah Y, Janssen HLA, Lim SG, et al. Ethics and hepatitis B cure research. Gut. 2017;66(3):389. https:\/\/doi.org\/10.1136\/gutjnl-2016-313009.","journal-title":"Gut"},{"issue":"7","key":"763_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545\u201358.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"763_CR8","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jiae248","volume":"230","author":"T Grudda","year":"2024","unstructured":"Grudda T, Thomas DL, Kirk GD, Mehta SH, Astemborski J, Lauer GM, et al. Hepatitis B virus DNA and RNA persist in liver after serologic recovery in persons with hepatitis C virus. J Infect Dis. 2024;230(6):1352\u20136.","journal-title":"J Infect Dis"},{"key":"763_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/PROM.S226936","volume":"11","author":"J Smith-Palmer","year":"2020","unstructured":"Smith-Palmer J, Cerri K, Sbarigia U, Chan E, Pollock R, Valentine W, et al. Impact of stigma on people living with chronic hepatitis B. Patient Relat Outcome Meas. 2020;11:95\u2013107.","journal-title":"Patient Relat Outcome Meas"},{"key":"763_CR10","doi-asserted-by":"publisher","unstructured":"Yendewa GA, Sellu EJ, Kpaka RA, James PB, Yendewa SA, Cummings PE et al. Measuring Stigma Associated with Hepatitis B Virus Infection in Sierra Leone: Validation of an Abridged Berger Stigma Scale. J Viral Hepat [Internet]. 2023;1\u20139. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/jvh.13838","DOI":"10.1111\/jvh.13838"},{"issue":"1","key":"763_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-023-17263-6","volume":"24","author":"M Toumi","year":"2024","unstructured":"Toumi M, Wallace J, Cohen C, Marshall C, Kitchen H, Macey J, et al. Experience and impact of stigma in people with chronic hepatitis B: A qualitative study in Asia, Europe, and the united States. BMC Public Health. 2024;24(1):1\u201314.","journal-title":"BMC Public Health"},{"issue":"5","key":"763_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/v12050515","volume":"12","author":"T Tu","year":"2020","unstructured":"Tu T, Block J, Wang S, Cohen C, Doulas M. The lived experience of chronic hepatitis B: A broader view of its impacts and why we need a cure. Viruses. 2020;12(5):515.","journal-title":"Viruses"},{"key":"763_CR13","doi-asserted-by":"publisher","unstructured":"Adda D, Wang S. A declaration from people living with hepatitis B: a call for a whole person approach. J Viral Hepat. 2023(7). https:\/\/doi.org\/10.1111\/jvh.13839.","DOI":"10.1111\/jvh.13839"},{"key":"763_CR14","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1097\/MJT.0000000000001651","volume":"31","author":"C Danielescu","year":"2024","unstructured":"Danielescu C, State M, Mateescu RB. Advances in the Pharmacological management of chronic hepatitis B. Am J Ther [Internet]. 2024;31:e280\u201385. Available from: www.americantherapeutics.com.","journal-title":"Am J Ther [Internet]"},{"key":"763_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/v13071341","author":"A Boyd","year":"2021","unstructured":"Boyd A, Dezanet LNC, Lacombe K, MDPI AG. Functional cure of hepatitis B virus infection in individuals with HIV-coinfection: a literature review. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13071341.","journal-title":"Viruses"},{"key":"763_CR16","unstructured":"Soriano V, Moreno-Torres V, de Mendoza C, Corral O, Barreiro P. Viral hepatitis in persons living with HIV in the Post-COVID Era. Vol. 25, AIDS reviews. Permanyer; 2023. pp. 1\u201313."},{"issue":"3","key":"763_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","volume":"4","author":"K Zhou","year":"2019","unstructured":"Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol Hepatol. 2019;4(3):227\u201338.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"763_CR18","doi-asserted-by":"crossref","unstructured":"Bollinger RC, Thio CL, Sulkowski MS, McKenzie-White J, Thomas DL, Flexner C. Addressing the global burden of hepatitis B virus while developing Long-Acting injectables for the prevention and treatment of HIV. The Lancet HIV. Volume 7. Elsevier Ltd; 2020. pp. e443\u20138.","DOI":"10.1016\/S2352-3018(19)30342-X"},{"issue":"7","key":"763_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1086\/507532","volume":"43","author":"V Levy","year":"2006","unstructured":"Levy V, Grant R. HIV\/AIDS: antiretroviral therapy for hepatitis B virus-HIV co-infected patients: promises and pitfalls. Clin Infect Dis. 2006;43(7):904\u201310.","journal-title":"Clin Infect Dis"},{"key":"763_CR20","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1097\/QAD.0000000000002941","volume":"35","author":"R Mican","year":"2021","unstructured":"Mican R, Busca Arenzana C, Vasquez J, Daroca G, Perez-Valero I, Martin-Carbonero L, et al. Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient with history of cured hepatitis B virus infection and poor immunological status. AIDS. 2021;35:1707\u20138.","journal-title":"AIDS"},{"key":"763_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.32314","volume":"76","author":"S Fung","year":"2022","unstructured":"Fung S, Choi H, Gehring A, Janssen H. Getting to HBV cure: the promising paths forward. Hepatology. 2022;76:233\u201350.","journal-title":"Hepatology"},{"issue":"S1","key":"763_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/liv.14837","volume":"41","author":"G Dusheiko","year":"2021","unstructured":"Dusheiko G. Hepatitis B, cure. How and when. Liver Int. 2021;41(S1):24\u20139.","journal-title":"Liver Int"},{"key":"763_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","volume":"67","author":"A Lok","year":"2017","unstructured":"Lok A, Zoulim F, Dusheiko G, Ghany M. Hepatitis B, cure. From discovery to regulatory approval. J Hepatol. 2017;67:847\u201361.","journal-title":"J Hepatol"},{"key":"763_CR24","doi-asserted-by":"crossref","unstructured":"Grossman CI, Ross AL, Auerbach JD, Ananworanich J, Dub\u00e9 K, Tucker JD et al. Towards Multidisciplinary HIV-Cure Research: Integrating Social Science with Biomedical Research. Trends Microbiol [Internet]. 2016 Jan [cited 2017 Jan 8];24(1):5\u201311. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=4698010&tool=pmcentrez&rendertype=abstract","DOI":"10.1016\/j.tim.2015.10.011"},{"key":"763_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25404","volume":"22","author":"K Dub\u00e9","year":"2019","unstructured":"Dub\u00e9 K, Auerbach JD, Stirratt MJ, Gaist P. Applying the behavioural and social sciences research (BSSR) functional framework to HIV cure research. J Int AIDS Soc. 2019;22:e25404.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"763_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S2055-6640(20)30027-3","volume":"5","author":"M Paximadis","year":"2019","unstructured":"Paximadis M, Perez patrigeon S, Rajasuriar R, Tatoud R, Scully E, Arbuthnot P. Hepatitis B and HIV-1 2019 IAS cure forum: lessons and benefits from interdisciplinary research. J Virus Erad. 2019;5(4):234\u201344.","journal-title":"J Virus Erad"},{"key":"763_CR27","first-page":"1","volume":"Feb","author":"J Sugarman","year":"2020","unstructured":"Sugarman J. Ethics of HIV and hepatitis B cure research. Curr Opin HIV AIDS. 2020;Feb:25:1\u20135.","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"763_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2023.100344","volume":"9","author":"M Kang","year":"2023","unstructured":"Kang M, Price JC, Peters MG, Lewin SR, Sulkowski M. Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV. J Virus Erad. 2023;9(3):100344.","journal-title":"J Virus Erad"},{"key":"763_CR29","doi-asserted-by":"crossref","unstructured":"Ibrahim Y, Cohen C, Araojo R, Merenda C, Dykstra S, Lee C. Attitudes towards clinical trial participation among people living with chronic hepatitis B. J Transl Sci. 2022;8(1):1-10.","DOI":"10.15761\/JTS.1000467"},{"issue":"4","key":"763_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2023.100354","volume":"9","author":"N Mohtashemi","year":"2023","unstructured":"Mohtashemi N, Dub\u00e9 K, Thio C, Song S, Patel S, Sugarman J, et al. Patient acceptability of, and attitudes towards, hepatitis B cure research \u2013 a scoping review and identification of knowledge gaps. J Virus Erad. 2023;9(4):100354.","journal-title":"J Virus Erad"},{"key":"763_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2147\/PPA.S238833","volume":"14","author":"F Hardstock","year":"2020","unstructured":"Hardstock F, Sbarigia U, Kocaata Z, Wilke T, Sylvester S. Preferences of patients with chronic hepatitis B - a discrete choice experiment on the acceptability of functional cure. Patient Prefer Adherence. 2020;14:613\u201324.","journal-title":"Patient Prefer Adherence"},{"key":"763_CR32","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/jvh.13592","volume":"28","author":"C Freeland","year":"2021","unstructured":"Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C. Cure everyone and vaccinate the rest: the patient perspective of future hepatitis B treatment. J Viral Hepat. 2021;28:1539\u201344.","journal-title":"J Viral Hepat"},{"key":"763_CR33","unstructured":"HBF. The Voice of the Patient: Living with Chronic Hepatitis B [Internet]. 2020 [cited 2024 Jul 6]. Available from: https:\/\/www.hepb.org\/assets\/Uploads\/ExPFDD-Report-HBF-10-1-2020.pdf"},{"issue":"8","key":"763_CR34","first-page":"1","volume":"3","author":"JA Richmond","year":"2018","unstructured":"Richmond JA, Ellard J, Wallace J, Thorpe R, Higgs P, Hellard M, et al. Achieving a hepatitis C cure: A qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia. Hepatol Med Policy. 2018;3(8):1\u20139.","journal-title":"Hepatol Med Policy"},{"key":"763_CR35","doi-asserted-by":"crossref","unstructured":"Zhang L, Liu Y, Tian J. Patient Preferences and Their Influence on Chronic Hepatitis B - A Review. Patient Prefer Adherence [Internet]. 2023;Volume 17:3119\u201324. Available from: https:\/\/www.dovepress.com\/patient-preferences-and-their-influence-on-chronic-hepatitis-b-a-revie-peer-reviewed-fulltext-article-PPA","DOI":"10.2147\/PPA.S433283"},{"key":"763_CR36","doi-asserted-by":"publisher","unstructured":"Bauquier C, Pr\u00e9au M. Contribution of HIV\/AIDS-related human and social sciences research to a better understanding of the challenges of hepatitis B prevention, diagnosis and care. p. 1166 Microorganisms. 2021. https:\/\/doi.org\/10.3390\/microorganisms9061166.","DOI":"10.3390\/microorganisms9061166"},{"issue":"1","key":"763_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-021-00398-8","volume":"5","author":"C Freeland","year":"2021","unstructured":"Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C, et al. Health-related quality of life for adults living with hepatitis B in the United States: a qualitative assessment. J Patient Rep Outcomes. 2021;5(1):121.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"763_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-024-18425-w","volume":"24","author":"C Freeland","year":"2024","unstructured":"Freeland C, Adjei C, Wallace J, Wang S, Hicks J, Adda D, et al. Survey of lived experiences and challenges in hepatitis B management and treatment. BMC Public Health. 2024;24(1):1\u20139.","journal-title":"BMC Public Health"},{"issue":"3","key":"763_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","volume":"11","author":"A Levy","year":"2008","unstructured":"Levy A, Kowdley K, Lloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: A multinational study of utilities from infected and uninfected persons. Value Health. 2008;11(3):527\u201338.","journal-title":"Value Health"},{"key":"763_CR40","doi-asserted-by":"crossref","unstructured":"Liang LY, Wong GLH. Unmet need in chronic hepatitis B Management. Vol. 25, clinical and molecular hepatology. Korean Association for the Study of the Liver; 2019. pp. 172\u201380.","DOI":"10.3350\/cmh.2018.0106"},{"issue":"4","key":"763_CR41","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2468-1253(23)00455-7","volume":"9","author":"C Freeland","year":"2024","unstructured":"Freeland C, Lo W, Kabagambe K, Wang S, Adda D, Graham C, et al. Urgent need for lived experience in hepatitis B guideline development. Lancet Gastroenterol Hepatol. 2024;9(4):282\u20134.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"763_CR42","first-page":"1","volume":"10","author":"Y Ibrahim","year":"2023","unstructured":"Ibrahim Y, Umstead M, Wang S, Cohen C. The impact of living with chronic hepatitis B on quality of life: implications for clinical management. J Patient Exp. 2023;10:1\u20139.","journal-title":"J Patient Exp"},{"issue":"1","key":"763_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11093-0","volume":"21","author":"C Freeland","year":"2021","unstructured":"Freeland C, Farrell S, Kumar P, et al. Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. BMC Public Health. 2021;21(1):1004.","journal-title":"BMC Public Health"},{"issue":"1","key":"763_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-18918-8","volume":"24","author":"C Freeland","year":"2024","unstructured":"Freeland C, Qureshi A, Wallace J, Kabagambe K, Desalegn H, Munoz C, et al. Hepatitis B discrimination: global responses requiring global data. BMC Public Health. 2024;24(1):1575.","journal-title":"BMC Public Health"},{"issue":"1","key":"763_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.15171\/jcs.2016.006","volume":"5","author":"L Valizadeh","year":"2016","unstructured":"Valizadeh L, Zamanzadeh V, Negarandeh R, Zamani F, Hamidia A, Zabihi A. Psychological reactions among patients with chronic hepatitis B: a qualitative study. J Caring Sci. 2016;5(1):57\u201366.","journal-title":"J Caring Sci"},{"issue":"1","key":"763_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12939-017-0637-4","volume":"16","author":"J Wallace","year":"2017","unstructured":"Wallace J, Pitts M, Liu C, Lin V, Hajarizadeh B, Richmond J, et al. More than a virus: A qualitative study of the social implications of hepatitis B infection in China. Int J Equity Health. 2017;16(1):1\u20137.","journal-title":"Int J Equity Health"},{"key":"763_CR47","volume":"21","author":"T Ezbarami","year":"2017","unstructured":"Ezbarami T, Hassani P, Zagheri Tafreshi M, Alavi Majd H. A qualitative study on individual experiences of chronic hepatitis B patients. Nurs Open. 2017;21:1004.","journal-title":"Nurs Open"},{"issue":"4","key":"763_CR48","doi-asserted-by":"publisher","first-page":"S517","DOI":"10.1093\/cid\/ciac718","volume":"75","author":"DL Thomas","year":"2022","unstructured":"Thomas DL, Kiser JJ, Baum MM. Long-acting treatments for hepatitis B. Clin Infect Dis. 2022;75(4):S517-24.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"763_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002470","volume":"14","author":"K Dub\u00e9","year":"2017","unstructured":"Dub\u00e9 K, Sylla L, Dee L, Taylor J, Evans D, Bruton C, et al. Research on HIV cure: mapping the ethics landscape. PLoS Med. 2017;14(12):e1002470.","journal-title":"PLoS Med"},{"key":"763_CR50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/1471-0528.12844","volume":"121","author":"M Brady","year":"2014","unstructured":"Brady M, Tolley E. Aligning product development and user perspectives: social-behavioural dimensions of multipurpose prevention technologies. BJOG: An International Journal of Obstetrics & Gynaecology. 2014;121:70\u20138.","journal-title":"BJOG: An International Journal of Obstetrics & Gynaecology"},{"issue":"6","key":"763_CR51","first-page":"348","volume":"13","author":"M Peters","year":"2017","unstructured":"Peters M, Locarnini S. New direct-acting antiviral agents and immunomodulators for hepatitis B virus infection. Gastroenterol Hepatol. 2017;13(6):348\u201356.","journal-title":"Gastroenterol Hepatol"},{"key":"763_CR52","doi-asserted-by":"publisher","unstructured":"Cornberg M, Suk-Fong Lok A, Terrault NA, Zoulim F, Treatment Endpoints HBV Conference, Faculty E aasld, Berg T et al. Guidance for Design and Endpoints of Clinical trials in Chronic Hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference\u2021. J Hepatol [Internet]. 2019;72:539\u201357. Available from: https:\/\/doi.org\/10.1016\/j.jhep.201","DOI":"10.1016\/j.jhep.201"},{"key":"763_CR53","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/MCG.0b013e318266fe70","volume":"47","author":"VK Amorosa","year":"2013","unstructured":"Amorosa VK, Aibana O, Shire NJ, Dorey-Stein Z, Ferrara T, Gilmore J, et al. Willingness to undergo a repeat liver biopsy among HIV\/Hepatitis C Virus-Coinfected and hepatitis C Virus-Monoinfected patients. J Clin Gastroenterol [Internet]. 2013;47:457\u201360. Available from: www.jcge.com.","journal-title":"J Clin Gastroenterol [Internet]"},{"key":"763_CR54","doi-asserted-by":"crossref","unstructured":"Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping Nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Vol. 185, antiviral research. Elsevier B.V.; 2021. pp. 1\u201314.","DOI":"10.1016\/j.antiviral.2020.104992"},{"key":"763_CR55","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.cgh.2018.02.037","volume":"16","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Stephanova M, Janssen H, et al. Effects of treatment of chronic hepatitis B virus infection on Patient-Reported outcomes. Clin Gastroenterol Hepatol. 2018;16:1641\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"19","key":"763_CR56","first-page":"18","volume":"3018","author":"K Dub\u00e9","year":"2019","unstructured":"Dub\u00e9 K, Barr L, Palm D, Brown B, Taylor J. Putting participants at the centre of HIV cure research. Lancet HIV. 2019;3018(19):18\u20139.","journal-title":"Lancet HIV"},{"issue":"1","key":"763_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-023-00675-8","volume":"8","author":"J Abbott","year":"2024","unstructured":"Abbott J, Aldhouse NVJ, Kitchen H, Pegram HC, Brown F, Macartney M, et al. A conceptual model for chronic hepatitis B and content validity of the hepatitis B quality of life (HBQOL) instrument. J Patient Rep Outcomes. 2024;8(1):29.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"763_CR58","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hep.21692","volume":"46","author":"BMR Spiegel","year":"2007","unstructured":"Spiegel BMR, Bolus R, Han S, Tong M, Esrailian E, Talley J, et al. Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: the hepatitis B quality of life instrument, version 1.0. Hepatology. 2007;46(1):113\u201321.","journal-title":"Hepatology"},{"key":"763_CR59","doi-asserted-by":"crossref","unstructured":"Hendriks S, Pearson SD. Assessing potential cures: are there distinctive elements of value beyond health gain? Journal of Comparative Effectiveness Research. Volume 10. Future Medicine Ltd.; 2021. pp. 255\u201365.","DOI":"10.2217\/cer-2020-0190"},{"key":"763_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2358-0","author":"A Corneli","year":"2018","unstructured":"Corneli A, Meagher K, Henderson G, Peay H, Rennie S. How biomedical HIV prevention trials incorporate behavioral and social sciences research: a typology of approaches. AIDS Behav. 2018. https:\/\/doi.org\/10.1007\/s10461-018-2358-0.","journal-title":"AIDS Behav"},{"issue":"12","key":"763_CR61","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/cid\/ciz669","volume":"70","author":"JZ Shing","year":"2020","unstructured":"Shing JZ, Ly KN, Xing J, Teshale EH, Jiles RB. Prevalence of hepatitis B virus infection among U.S. adults aged 20\u201359 years with a history of injection drug use: national health and nutrition examination survey, 2001\u20132016. Clin Infect Dis. 2020;70(12):2619\u201327.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"763_CR62","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","volume":"6","author":"B Julg","year":"2019","unstructured":"Julg B, Dee L, Ananworanich J, Barouch D, Bar K, Caskey M, et al. Recommendations for analytical treatment interruptions in HIV research Trials. Report of a consensus meeting. Lancet HIV. 2019;6(4):e259\u201368.","journal-title":"Lancet HIV"},{"key":"763_CR63","doi-asserted-by":"crossref","unstructured":"Lo B, Grady C. Ethical Considerations in HIV Cure Research: Points to Consider. Curr Opin HIV AIDS [Internet]. 2013 May [cited 2014 Jul 3];8(3):243\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23422260","DOI":"10.1097\/COH.0b013e32835ea1c5"},{"issue":"83","key":"763_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12910-021-00651-1","volume":"22","author":"K Dub\u00e9","year":"2021","unstructured":"Dub\u00e9 K, Kanazawa J, Taylor J, Dee L, Jones N, Roebuck C, et al. Ethics of HIV Cure Research: An Unfinished Agenda. BMC Med Ethics. 2021;22(83):1\u201314. https:\/\/doi.org\/10.1186\/s12910-021-00651-1.","journal-title":"BMC Med Ethics"},{"key":"763_CR65","unstructured":"Lim SG, Der Teo AE, Shih-Yen Chan E, Phyo WW, Yu Chen DH, Hargreaves CA. Stopping Nucleos(t)ide analogues in chronic hepatitis B using HbsAg thresholds: A Meta-Analysis and Meta-Regression. Clin Gastroenterol Hepatol 2024;Jun 11:S1542-3565(24)00516-0."},{"key":"763_CR66","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1136\/gutjnl-2019-319648","volume":"68","author":"JH Kao","year":"2019","unstructured":"Kao JH, Berg T. Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop? Gut. 2019;68:2105\u20136.","journal-title":"Gut"},{"issue":"4","key":"763_CR67","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","volume":"15","author":"JH Kao","year":"2021","unstructured":"Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int. 2021;15(4):833\u201351.","journal-title":"Hepatol Int"},{"issue":"5","key":"763_CR68","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","volume":"78","author":"F van B\u00f6mmel","year":"2023","unstructured":"van B\u00f6mmel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, et al. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. J Hepatol. 2023;78(5):926\u201336.","journal-title":"J Hepatol"},{"issue":"4","key":"763_CR69","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1089\/aid.2019.0118","volume":"36","author":"JSY Lau","year":"2020","unstructured":"Lau JSY, Smith MZ, Allan B, Martinez C, Power J, Lewin SR, et al. Perspectives on analytical treatment interruptions in people living with HIV and their health care providers in the landscape of HIV cure-focused studies. AIDS Res Hum Retroviruses. 2020;36(4):260\u20137.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"763_CR70","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1089\/aid.2014.0219","volume":"31","author":"GE Henderson","year":"2015","unstructured":"Henderson GE. The ethics of HIV \u2018Cure\u2019 research: what can we learn from consent forms? AIDS Res Hum Retroviruses. 2015;31(1):56\u201363.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"763_CR71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2055-6640(20)31143-2","volume":"1","author":"H Peay","year":"2015","unstructured":"Peay H, Henderson G. What motivates participation in HIV cure trials? A call for Real-Time assessment to improve informed consent. J Virus Erad. 2015;1(1):51\u20133.","journal-title":"J Virus Erad"},{"key":"763_CR72","doi-asserted-by":"publisher","unstructured":"Dub\u00e9 K, Kanazawa J, Patel H, Louella M, Sylla L, Sheehy J, et al. Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States. BMC Med Ethics. 2022;39. https:\/\/doi.org\/10.1186\/s12910-022-00780-1.","DOI":"10.1186\/s12910-022-00780-1"},{"key":"763_CR73","doi-asserted-by":"publisher","unstructured":"Dub\u00e9 K, Kanazawa J, Louella M, Sheehy J, Sauceda JA, Peluso MJ et al. Considerations for Designing and Implementing Combination HIV Cure Trials: Findings from a Qualitative In-Depth Interview Study in the United States. AIDS Res Ther [Internet]. 2021;28(75):1\u201317. Available from: https:\/\/doi.org\/10.21203\/rs.3.rs-424206\/v1","DOI":"10.21203\/rs.3.rs-424206\/v1"},{"key":"763_CR74","doi-asserted-by":"publisher","unstructured":"Dub\u00e9 K, Morton T, Fox L, Dee L, Palm D, Villa TJ et al. A Partner Protection Package for HIV Cure-Related Trials involving Analytical Treatment Interruptions. Lancet Infectious Diseases [Internet]. 2023;23(10):e418-30. Available from: https:\/\/doi.org\/10.1016\/S1473-3099","DOI":"10.1016\/S1473-3099"},{"issue":"1","key":"763_CR75","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/aid.2021.0023","volume":"38","author":"K Dub\u00e9","year":"2022","unstructured":"Dub\u00e9 K, Kanazawa JT, Campbell C, Boone CA, Maragh-Bass A, Campbell DM, et al. Considerations for increasing racial, ethnic, gender and sexual diversity in HIV cure-related research with analytical treatment interruptions: a qualitative inquiry. AIDS Res Hum Retroviruses. 2022;38(1):50\u201363.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"20305","key":"763_CR76","first-page":"1","volume":"18","author":"BM Meier","year":"2015","unstructured":"Meier BM, Gelpi A, Kavanagh MM, Forman L, Amon JJ. Employing human rights frameworks to realize access to an HIV cure. J Int AIDS Soc. 2015;18(20305):1\u20137.","journal-title":"J Int AIDS Soc"},{"key":"763_CR77","unstructured":"Dub\u00e9 K, Perez-Brumer A. Call for Justice-Informed HIV Cure Trials with ATIs. Lancet HIV [Internet]. 2024;[Online First]:1\u20132. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235230182400002X"},{"key":"763_CR78","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(23)00315-1","volume":"9","author":"M Delphin","year":"2024","unstructured":"Delphin M, Mohammed K, Downs L, Lumley S, Waddilove E, Okanda D, et al. Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection. Lancet Gastroenterol Hepatol. 2024;9:383\u201392.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"763_CR79","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","volume":"115","author":"JK Lim","year":"2020","unstructured":"Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM, et al. Prevalence of chronic hepatitis B virus infection in the United States. Am J Gastroenterol. 2020;115:1429\u201338.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"763_CR80","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jvh.13874","volume":"30","author":"N Ferrante","year":"2023","unstructured":"Ferrante N, Kallan M, Sukkestad D, Kodani M, Kitahata M, Cachay E, et al. Prevalence and determinants of hepatitis delta virus infection among HIV\/Hepatitis B-Coinfected adults in care in the united States. J Viral Hepat. 2023;30(11):879\u201388.","journal-title":"J Viral Hepat"},{"issue":"4","key":"763_CR81","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/OLQ.0000000000001359","volume":"48","author":"H Roberts","year":"2021","unstructured":"Roberts H, Jiles R, Harris AM, Gupta N, Teshale E. Incidence and prevalence of sexually transmitted hepatitis B, United States, 2013\u20132018. Sex Transm Dis. 2021;48(4):305\u20139.","journal-title":"Sex Transm Dis"},{"key":"763_CR82","doi-asserted-by":"crossref","unstructured":"Wong RJ, Brosgart CL, Welch S, Block T, Chen M, Cohen C et al. An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States. Hepatology [Internet]. 2021;74(2):2021. Available from: https:\/\/www.plan-a.com\/","DOI":"10.1002\/hep.31782"},{"key":"763_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cld.732","volume":"12","author":"B Hyun Kim","year":"2018","unstructured":"Hyun Kim B, Ray Kim W, John Wiley and Sons Inc. Epidemiology of hepatitis B virus infection in the United States. Clin Liver Dis. 2018;12:1\u20134.","journal-title":"Clin Liver Dis"},{"key":"763_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1437502","volume":"12","author":"F Borondy-Jenkins","year":"2024","unstructured":"Borondy-Jenkins F, Ansah B, Chen J, Goldring A, Ibrahim Y, Issa S, et al. Global hepatitis B and D community advisory board: expectations, challenges, and lessons learned. Front Public Health. 2024;12:1437502.","journal-title":"Front Public Health"},{"key":"763_CR85","doi-asserted-by":"crossref","unstructured":"Karris MY, Dub\u00e9 K, Moore AA. What lessons it might teach us? Community engagement in HIV research. Curr Opin HIV AIDS. 2020 Mar;15(2):142\u20139","DOI":"10.1097\/COH.0000000000000605"},{"issue":"S7","key":"763_CR86","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25174","volume":"21","author":"S Day","year":"2018","unstructured":"Day S, Blumberg M, Vu T, Zhao Y, Rennie S, Tucker JD. Stakeholder engagement to inform HIV clinical trials: a systematic review of the evidence. J Int AIDS Soc. 2018;21(S7):e25174.","journal-title":"J Int AIDS Soc"},{"key":"763_CR87","unstructured":"NASEM. Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research [Internet]. 2022. Available from: https:\/\/www.nationalacademies.org\/our-work\/improving-the-representation-of-women-and-underrepresented-minorities-in-clinical-trials-and-research"},{"issue":"1","key":"763_CR88","first-page":"1","volume":"9","author":"N Mofokeng","year":"2023","unstructured":"Mofokeng N, Maponga TG, van Schalkwyk M, Hugo S, Morobadi MD, Vawda S, et al. Barriers that prevent adults living with HBV infection from participating in clinical research: experience from South Africa. J Virus Erad. 2023;9(1):1\u20134.","journal-title":"J Virus Erad"},{"issue":"7","key":"763_CR89","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/10810730.2024.2362882","volume":"29","author":"B Zovich","year":"2024","unstructured":"Zovich B, Block SJ, Borondy-Jenkins F, Chen T, Moraras K, Afoakwah J, et al. The role of culturally appropriate mediated communication strategies to reduce hepatitis B and liver cancer disparities. J Health Commun. 2024;29(7):440\u20139.","journal-title":"J Health Commun"},{"issue":"7","key":"763_CR90","first-page":"2825","volume":"4","author":"P Matthews","year":"2022","unstructured":"Matthews P, Jack K, Wang S, Abbott J, Bryce K, Cheng B, et al. A call for advocacy and patient voice to eliminate hepatitis B virus infection. Lancet Gastroenterol Hepatol. 2022;4(7):2825.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"763_CR91","unstructured":"UNAIDS AVAC. Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials [Internet]. 2011. Available from: http:\/\/www.avac.org\/good-participatory-practice"},{"key":"763_CR92","volume":"5","author":"L Newton","year":"2019","unstructured":"Newton L, Necochea R, Palm D, Taylor J, Barr L, Patel H. Revisiting the \u2018sterilising cure\u2019 terminology: a call for more patient-centred perspectives on HIV cure-related research. J Virus Erad. 2019;5:e18\u201320.","journal-title":"J Virus Erad"},{"issue":"1","key":"763_CR93","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/0963662506071287","volume":"16","author":"MW Bauer","year":"2007","unstructured":"Bauer MW, Allum N, Miller S. What can we learn from 25 years of PUS survey research? Liberating and expanding the agenda. Public Understand Sci. 2007;16(1):79\u201395. https:\/\/doi.org\/10.1177\/0963662506071287.","journal-title":"Public Understand Sci"},{"key":"763_CR94","doi-asserted-by":"crossref","unstructured":"Noorman MAJ, de Wit JBF, Marcos TA, Stutterheim SE, Jonas KJ, den Daas C. The importance of social engagement in the development of an HIV cure: A systematic review of stakeholder perspectives. AIDS and Behavior. Volume 27. Springer; 2023. pp. 3789\u2013812.","DOI":"10.1007\/s10461-023-04095-z"},{"key":"763_CR95","unstructured":"NASEM. Assessing Meaningful Community Engagement. A Conceptual Model to Advance Health Equity through Transformed Systems for Health [Internet]. 2022 [cited 2022 Oct 3]. Available from: https:\/\/nam.edu\/assessing-meaningful-community-engagement-a-conceptual-model-to-advance-health-equity-through-transformed-systems-for-health\/"},{"key":"763_CR96","doi-asserted-by":"publisher","unstructured":"Dub\u00e9 K, Peterson B, Jones NL, Onorato A, Carter WB, Dannaway C et al. Community Engagement Group Model in Basic and Biomedical Research: Lessons Learned from the BEAT-HIV Delaney Collaboratory Towards an HIV-1 Cure. Res Involv Engagem [Internet]. 2023;9(39):1\u201317. Available from: https:\/\/researchinvolvement.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40900-023-00449-y","DOI":"10.1186\/s40900-023-00449-y"},{"issue":"10 Suppl 1","key":"763_CR97","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1097\/MLR.0000000000000953","volume":"56","author":"C Wilkins","year":"2018","unstructured":"Wilkins C. Effective engagement requires trust and being trustworthy. Med Care. 2018;56(10 Suppl 1):S6\u20138.","journal-title":"Med Care"},{"issue":"11","key":"763_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v14112542","volume":"14","author":"J Wallace","year":"2022","unstructured":"Wallace J, Richmond J, Howell J, Hajarizadeh B, Power J, Treloar C, et al. Exploring the public health and social implications of future curative hepatitis B interventions. Viruses. 2022;14(11):1\u201314.","journal-title":"Viruses"},{"issue":"5","key":"763_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2023-080658","volume":"14","author":"M Jackson","year":"2024","unstructured":"Jackson M, Ibrahim Y, Freeland C, Jacob S, Zovich B, Cohen C. Barriers to accessing hepatitis B medication: A qualitative study from the USA and Canada. BMJ Open. 2024;14(5):1\u20136.","journal-title":"BMJ Open"},{"issue":"10","key":"763_CR100","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/GIM.0b013e31815699d0","volume":"9","author":"MJ Khoury","year":"2007","unstructured":"Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore Ca, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med. 2007;9(10):665\u201374. https:\/\/doi.org\/10.1097\/GIM.0b013e31815699d0.","journal-title":"Genet Med"},{"issue":"5","key":"763_CR101","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/eahr.500139","volume":"44","author":"RL Walker","year":"2022","unstructured":"Walker RL, MacKay D, Waltz M, Lyerly AD, Fisher JA. Ethical criteria for improved human subject protections in phase I healthy volunteer trials. Ethics & Human Research. 2022;44(5):2\u201321.","journal-title":"Ethics & Human Research"},{"issue":"1","key":"763_CR102","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2352-3018(20)30234-4","volume":"8","author":"SR Lewin","year":"2021","unstructured":"Lewin SR, Attoye T, Bansbach C, Doehle B, Dub\u00e9 K, Dybul M, et al. Multi-Stakeholder consensus on a target product profile for an HIV cure. Lancet HIV. 2021;8(1):e42\u201350.","journal-title":"Lancet HIV"},{"key":"763_CR103","doi-asserted-by":"crossref","unstructured":"Lewin SR, Bansbach C, Kemps D, Mathae L, Das KT, McCune JM et al. Target Product Profile for Cell-Based and Gene-Based Therapies to Achieve a Cure for HIV. Lancet HIV [Internet]. 2025;(24). Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352301824002777","DOI":"10.1016\/S2352-3018(24)00277-7"},{"issue":"28","key":"763_CR104","doi-asserted-by":"publisher","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","volume":"67","author":"Y Hutin","year":"2018","unstructured":"Hutin Y, NAsrullah M, Easterbrook P, Nguimfack B, Burrone E, Averhoff F, et al. Access to treatment for hepatitis B virus infection - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(28):773\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"763_CR105","doi-asserted-by":"crossref","unstructured":"Howell J, Seaman C, Wallace J, Xiao Y, Scott N, Davies J, et al. Pathway to global elimination of hepatitis B: HBV cure is just the first step. Hepatology. 2023;78:976\u201390.","DOI":"10.1097\/HEP.0000000000000430"},{"key":"763_CR106","doi-asserted-by":"publisher","unstructured":"Carrieri P, Carrat F, Di Beo V, Bourli\u00e8re M, Barr\u00e9 T, De Ledinghen V, et al. Severe liver fibrosis in the HCV cure era: major effects of social vulnerability, diabetes, and unhealthy behaviors. HEP Rep 2022;4(6):100481. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100481.","DOI":"10.1016\/j.jhepr.2022.100481"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00763-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00763-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00763-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:03:42Z","timestamp":1769609022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00763-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00763-y","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,8]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"K.D. provides consulting services for Gilead Sciences, Inc. and AbbVie, Inc., unrelated to this manuscript. C.C. serves on patient advisory councils for Gilead Sciences, Inc. and GSK, with support paid to the Hepatitis B Foundation. Y.I. serves on a Roche steering committee, with support paid to the Hepatitis B Foundation. The Hepatitis B Foundation receives education and public health grants from Gilead Sciences, Inc., GSK, Vir, Roche, and Dynavax Technologies. E.R.C. receives payments from Gilead Sciences, Inc., unrelated to this manuscript. S.W. has received funding from Gilead Sciences, Inc. (paid to the institution) and holds unpaid roles with the Hepatitis B Foundation, HepBCommunity.org Steering Committee, AASLD Patient Advisory Board \u2013 HBV Special Interest Group, and the HBV Forum Steering Committee. K.M. has received grants from Gilead Sciences, Inc. and GSK (ViiV), paid to the institution. A.Y.K. plays a leadership role with the AASLD HBV Treatment Guidelines. J.S. is a consultant for Merck KGaA, IQVIA, and Merck, as well as a member of the Clinical Advisory Committee for Aspen Neurosciences, unrelated to this manuscript. D.L.T. is a scientific advisor to Excision Biosciences, a company working on an HBV cure. D.B. receives grant support, paid to the institution, from Gilead Sciences, Inc., unrelated to this manuscript. Other authors have no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}